The Ketamine Research Foundation is proud to announce full FDA and IRB approval for Conscious Dying/Conscious Living, our protocol providing Ketamine Assisted Psychotherapy for those facing death with conscious intent.
This program is the first of its kind. It provides a full therapeutic strategy for palliative care and hospice practitioners and programs that attend to the core emotional, spiritual, and relationship needs of those aware they will face death in a year or less. We intend this as a model pilot demonstration that will influence the humanization of end-of-life care. It is our hope that our Conscious Dying/Conscious Living Research Protocol will be successful in enhancing realization in those facing imminent death and engender positive choices and attitudes for life in remaining time.
To date there have been no published studies on the use of KAP in individuals with terminal illness. KAP combines the use of ketamine pharmacotherapy with psychotherapy. This novel treatment has shown benefit in self-realization, and the mitigation and alleviation of emotional pain, dysphoria, depression, and Post-Traumatic Stress Disorder.
Our beneficial use of KAP clinically with patients facing death has fostered our large study of 124 subjects in five sites across the US:
Bay Area, CA
Salt Lake City, UT